| Line Item | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|
| Profit or loss [abstract] | ||||
| Revenue | ||||
| Cost of Revenue | ||||
| Gross income before impact of changes in fair value | ||||
| Unrealized changes to fair value adjustments of biological assets | ||||
| Loss from fair value changes realized in the current year | ||||
| Gross profit | ||||
| Research and Development Expense | ||||
| Selling, General and Administrative Expense | ||||
| Operating Income | ||||
| Other expenses, net | ||||
| Changes in the fair value of financial assets through profit or loss, net | ||||
| Total expenses recognized from share-based payment transactions | ||||
| Operating profit (loss) | ||||
| Interest Income | ||||
| Financing expenses | ||||
| Financing expenses (income), net | ||||
| Profit (loss) before taxes on income | ||||
| Tax (expense) benefit | ||||
| Total comprehensive profit (loss) for the year | ||||
| Attribution of net profit (loss) for the year: | ||||
| Net Income | ||||
| Net Income Attributable to Noncontrolling Interest | ||||
| Total |